2025 annual financial data
Allogene Therapeutics 2025 Operating margin
Allogene Therapeutics 2025 operating margin with verified reported values.
Direct answer
Operating margin was Not calculable.
Operating income was -206,933,000 USD and net income was -190,886,000 USD.
Operating cash flow was -149,246,000 USD.
Get free Allogene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -206,933,000 USD
- Net income
- -190,886,000 USD
- Operating cash flow
- -149,246,000 USD